tradingkey.logo
tradingkey.logo

ImmuCell Corp

ICCC
View Detailed Chart
6.330USD
-0.200-3.06%
Market hours ETQuotes delayed by 15 min
19.11MMarket Cap
LossP/E TTM

ImmuCell Corp

6.330
-0.200-3.06%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.06%

5 Days

+4.28%

1 Month

-3.65%

6 Months

+2.43%

Year to Date

+2.93%

1 Year

+26.35%

View Detailed Chart

TradingKey Stock Score of ImmuCell Corp

Currency: USD Updated: 2026-03-27

Key Insights

ImmuCell Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ImmuCell Corp's Score

Industry at a Glance

Industry Ranking
112 / 157
Overall Ranking
336 / 4542
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

ImmuCell Corp Highlights

StrengthsRisks
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.64M.
Undervalued
The company’s latest PE is -56.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.84M shares, decreasing 4.61% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 150.69K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.54.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ImmuCell Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ImmuCell Corp Info

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Ticker SymbolICCC
CompanyImmuCell Corp
CEOte Boekhorst (Olivier)
Websitehttps://immucell.com/
KeyAI